Kurt J. Hilzinger, Director at Outlook Therapeutics, Inc. (OTLK), bought 18,354 shares at $0.51 ($10K) on 2018-12-27, disclosed to the SEC on 2018-12-28.
Open-market purchase of $10k OTLK by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.54 | 5,714 | $3K | 32.0% |
| 2 | $0.51 | 730 | $372 | 3.9% |
| 3 | $0.52 | 11,910 | $6K | 64.2% |
| Total | $0.53 avg | 18,354 | $10K | 100% |
| Filing → |
| OTLK | BUY | 2022-10-03 | $163K | — | Filing → |
| OTLK | BUY | 2022-03-03 | $47K | — | Filing → |
| OTLK | BUY | 2022-02-28 | $130K | — | Filing → |